Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2).

In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. MASK (Mobile Airways Sentinel NetworK) (1), a new development of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative (2), and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health) (3), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs—centred around the patient with rhinitis and using mHealth monitoring of environmental exposure.

[1]  K. Hurrelmann,et al.  Concept and Strategy for Implementing the National Action Plan on Health Literacy in Germany , 2020, European Journal of Public Health.

[2]  Airways ICPs initiative,et al.  ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”: AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project , 2019 .

[3]  P. Gergen,et al.  Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes , 2019, The Journal of allergy and clinical immunology.

[4]  J. Bousquet,et al.  Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases , 2019, Clinical and Translational Allergy.

[5]  D. Campbell-Lendrum,et al.  Environmental risks and non-communicable diseases , 2019, BMJ.

[6]  D. Campbell-Lendrum,et al.  Climate change, air pollution and noncommunicable diseases , 2018, Bulletin of the World Health Organization.

[7]  T. Keil,et al.  Allergy and atopy from infancy to adulthood: Messages from the German birth cohort MAS. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  Todor A Popov,et al.  ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy” , 2019, Allergy.

[9]  V. Jormanainen.  Large-scale implementation and adoption of the Finnish national Kanta services in 2010–2017: a prospective, longitudinal, indicator-based study , 2018, Finnish Journal of eHealth and eWelfare.

[10]  T. To,et al.  Country activities of Global Alliance against Chronic Respiratory Diseases (GARD): focus presentations at the 11th GARD General Meeting, Brussels. , 2018, Journal of thoracic disease.

[11]  Rosalind W. Picard,et al.  MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence , 2018, Clinical and Translational Allergy.

[12]  Daniel Laune,et al.  POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project , 2018, Clinical and Translational Allergy.

[13]  P. Hellings,et al.  Nasal hyperreactivity in rhinitis: A diagnostic and therapeutic challenge , 2018, Allergy.

[14]  A. Leunig,et al.  mySinusitisCoach: patient empowerment in chronic rhinosinusitis using mobile technology. , 2018, Rhinology.

[15]  J. Bousquet,et al.  Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. , 2018, The journal of allergy and clinical immunology. In practice.

[16]  T. To,et al.  A strategy for measuring health outcomes and evaluating impacts of interventions on asthma and COPD-common chronic respiratory diseases in Global Alliance against Chronic Respiratory Diseases (GARD) countries. , 2018, Journal of thoracic disease.

[17]  A. Sheikh,et al.  Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study , 2018, Allergy. European Journal of Allergy and Clinical Immunology.

[18]  J. Bousquet,et al.  Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management , 2018, Clinical and Translational Allergy.

[19]  Rachel Nadif,et al.  Indoor mould exposure, asthma and rhinitis: findings from systematic reviews and recent longitudinal studies , 2018, European Respiratory Review.

[20]  B. Bender,et al.  Integrated behavioral health care for management of stress in allergic diseases. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[21]  R. Rajah,et al.  The perspective of healthcare providers and patients on health literacy: a systematic review of the quantitative and qualitative studies , 2018, Perspectives in public health.

[22]  I. Annesi-Maesano,et al.  External exposome and allergic respiratory and skin diseases , 2018, The Journal of allergy and clinical immunology.

[23]  A. Sheikh,et al.  国际过敏与鼻科学共识声明 : 变应性鼻炎 , 2018 .

[24]  A. Sheikh,et al.  The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study , 2018, Allergy.

[25]  Á. Cruz,et al.  Global Alliance against Chronic Respiratory Diseases (GARD) Brazil success case: overcoming barriers. , 2018, Journal of thoracic disease.

[26]  Yen-Kuang Lin,et al.  Anthropological and sociological perspectives of medical professionalism , 2018, Ci ji yi xue za zhi = Tzu-chi medical journal.

[27]  A. Sheikh,et al.  The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. , 2017, Journal of investigational allergology & clinical immunology.

[28]  E. Valovirta,et al.  Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy , 2017, The Journal of allergy and clinical immunology.

[29]  H. Schünemann,et al.  [GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health]. , 2018, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[30]  J. Bousquet,et al.  European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017) , 2017, Clinical and Translational Allergy.

[31]  A. Sheikh,et al.  CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report , 2017, Clinical and Translational Allergy.

[32]  J. Bousquet,et al.  Work productivity in rhinitis using cell phones: The MASK pilot study , 2017, Allergy.

[33]  Joaquim Mullol,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision , 2017, The Journal of allergy and clinical immunology.

[34]  O. Mayora,et al.  Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[35]  J. Bousquet,et al.  EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. , 2017, Rhinology.

[36]  T. H. Nguyen,et al.  Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Respiratory medicine.

[37]  D. Ryan,et al.  Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement , 2017, Allergy.

[38]  P Demoly,et al.  Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK‐rhinitis study , 2017, Allergy.

[39]  J. Bousquet,et al.  The Finnish Allergy Programme 2008–2018 works , 2017, European Respiratory Journal.

[40]  J. Bousquet,et al.  Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report , 2017, Clinical and Translational Allergy.

[41]  A. Sheikh,et al.  Realising the potential of mHealth to improve asthma and allergy care: how to shape the future , 2017, European Respiratory Journal.

[42]  Richard Parker,et al.  The use of mobile applications to support self-management for people with asthma: a systematic review of controlled studies to identify features associated with clinical effectiveness and adherence , 2017, J. Am. Medical Informatics Assoc..

[43]  T. Haahtela,et al.  The Finnish experience to save asthma costs by improving care in 1987‐2013 , 2017, The Journal of allergy and clinical immunology.

[44]  Todor A Popov,et al.  ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle , 2016, Clinical and Translational Allergy.

[45]  P. Gergen,et al.  Asthma phenotypes in inner-city children. , 2016, The Journal of allergy and clinical immunology.

[46]  P. Gergen,et al.  Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents. , 2016, The Journal of allergy and clinical immunology.

[47]  P. Gergen,et al.  Pathways through which asthma risk factors contribute to asthma severity in inner-city children. , 2016, The Journal of allergy and clinical immunology.

[48]  Philip A Hines,et al.  Addressing the crisis of tomorrow: the sustainability of European health systems. EPC Policy Brief, 21 September 2016 , 2016 .

[49]  A. Sheikh,et al.  The PRISMS taxonomy of self-management support: derivation of a novel taxonomy and initial testing of its utility , 2016, Journal of health services research & policy.

[50]  Erle C. Ellis,et al.  The Anthropocene is functionally and stratigraphically distinct from the Holocene , 2016, Science.

[51]  Helen K. Reddel,et al.  A summary of the new GINA strategy: a roadmap to asthma control , 2015, European Respiratory Journal.

[52]  Subhrendu K. Pattanayak,et al.  Safeguarding human health in the Anthropocene epoch: report of The Rockefeller Foundation–Lancet Commission on planetary health , 2015, The Lancet.

[53]  M. Rosenberg,et al.  Employers’ views on the promotion of workplace health and wellbeing: a qualitative study , 2015, BMC Public Health.

[54]  J. Krapels,et al.  Health, wellbeing and productivity in the workplace: A Britain's Healthiest Company summary report , 2015 .

[55]  V. Jormanainen.  [Introduction of Kanta services between 2010 and 2014]. , 2015, Duodecim; laaketieteellinen aikakauskirja.

[56]  D. Postma,et al.  Integrated care pathways for airway diseases (AIRWAYS-ICPs) , 2014, European Respiratory Journal.

[57]  C. Robertson,et al.  Outcomes of childhood asthma to the age of 50 years. , 2014, The Journal of allergy and clinical immunology.

[58]  A. Buist,et al.  Complementing the randomized controlled trial evidence base. Evolution not revolution. , 2014, Annals of the American Thoracic Society.

[59]  M. Sofiev,et al.  A numerical model of birch pollen emission and dispersion in the atmosphere. Description of the emission module , 2012, International Journal of Biometeorology.

[60]  H. Goossens,et al.  EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists , 2012, Rhinology journal.

[61]  H. Goossens,et al.  EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. , 2012, Rhinology.

[62]  C. Rhee,et al.  Sublingual immunotherapy in allergic rhinitis , 2011, Asia Pacific allergy.

[63]  P. Bossuyt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations , 2011, Allergy.

[64]  S. Michie,et al.  The behaviour change wheel: A new method for characterising and designing behaviour change interventions , 2011, Implementation science : IS.

[65]  V. Kinnula,et al.  The 10-year COPD Programme in Finland: effects on quality of diagnosis, smoking, prevalence, hospital admissions and mortality. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[66]  P. Jousilahti,et al.  No increase in the prevalence of COPD in two decades , 2010, European Respiratory Journal.

[67]  I. Annesi-Maesano,et al.  Under‐report and underdiagnosis of chronic respiratory diseases in an African country , 2009, Allergy.

[68]  J. Bourbeau,et al.  Promoting effective self-management programmes to improve COPD , 2009, European Respiratory Journal.

[69]  S. Dinneen.  Structured education for people with type 2 diabetes , 2008, BMJ : British Medical Journal.

[70]  A. Sheikh,et al.  Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. , 2007, The Journal of allergy and clinical immunology.

[71]  J. Bousquet,et al.  Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. , 2007 .

[72]  M Kaila,et al.  A 10 year asthma programme in Finland: major change for the better , 2006, Thorax.

[73]  P. Howarth,et al.  ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy , 2004, Allergy.

[74]  Ann C. Greiner,et al.  The 1st Annual Crossing the Quality Chasm Summit: A Focus on Communities , 2004 .

[75]  Michael J. Hensley,et al.  Sleep apnoea. , 2003, Clinical evidence.

[76]  B. Duncan.  Health policy in the European Union: how it's made and how toinfluence it , 2002, BMJ : British Medical Journal.

[77]  R. Pauwels,et al.  Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.

[78]  A. Buist,et al.  A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. , 1994, American journal of respiratory and critical care medicine.